A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

RecruitingPhase 2/3

Long-term Extension Study for Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies

Who can join

Ages 60 and older · All sexes

Full eligibility criteria

Inclusion Criteria:

* Participants who were enrolled and received treatment with JNJ-81201887 or sham in a parent clinical study (81201887MDG2001, 81201887MDG1003)
* Females (women of childbearing potential), male participants, and partners of male participants will not be required to use contraception in this LTE study
* Must sign an informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study. The ICF may be signed by an impartial witness and/or legally designated representative depending on national/local regulations

Exclusion Criteria:

* There are no exclusion criteria for this LTE study

About the study

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.

What is being tested

JNJ-81201887 (drug)
Sham Procedure (other)

Sponsor: Janssen Research & Development, LLC · Participants: 274 · Started: Sep 19, 2024

Contact the study team

Study Contact · Phone: 844-434-4210

Official record on ClinicalTrials.gov — NCT06635148

Locations in the U.S.

Arizona	Retina Associates Southwest PC, Tucson
California	Retina Consultants of Orange County, Fullerton Shiley Eye Institute Jacobs Retina Center, La Jolla California Retina Consultants, Oxnard California Eye Medical Specialists, Pasadena Retina Consultants San Diego, Poway Bay Area Retina Associates, Walnut Creek
Florida	Retina Group of Florida, Fort Lauderdale VitreoRetinal Associates, PA, Gainesville Retina Specialty Institute, Pensacola Retina Vitreous Associates of Florida, St. Petersburg
Georgia	Georgia Retina, Marietta Marietta Eye Clinic, Marietta
Illinois	University Retina, Lemont
Indiana	Midwest Eye Institute, Carmel
Maine	Maine Eye Center, Portland
Maryland	Retina Specialists, Baltimore The Retina Group of Washington, Chevy Chase Cumberland Valley Retina Consultants, Hagerstown
Massachusetts	Ophthalmic Consultants of Boston, Boston
Michigan	Foundation for Vision Research, Grand Rapids
Minnesota	Retina Consultants of Minnesota, Saint Louis Park
Missouri	The Retina Institute, St Louis
Nevada	Sierra Eye Associates, Reno
New York	Retina-Vitreous Surgeons of Central New York, Liverpool
North Carolina	Asheville Eye Associates - Western Carolina Retinal Associates, Asheville Duke Eye Center, Durham Graystone Eye, Hickory NC Retina Associates, Wake Forest
Ohio	Cincinnati Eye Institute, Cincinnati Cleveland Clinic Main Campus, Cleveland
Oregon	Verum Research LLC, Eugene Cascade Medical Research Institute, LLC, Springfield
Pennsylvania	Erie Retina Research, Erie
South Carolina	Charleston Neuroscience Institute, LLC, Beaufort
Texas	Austin Clinical Research, Austin Texas Retina Associates, Dallas UT Southwestern Medical Center, Dallas Retina Associates Of South Texas P A, San Antonio Retina Consultants of Texas, The Woodlands Strategic Clinical Research Group, Willow Park
Utah	University of Utah, Salt Lake City
Virginia	Piedmont Eye Center, Lynchburg Wagner Kapoor Research institute, Norfolk
Washington	Spokane Eye Clinical Research, Spokane

Conditions

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.